<DOC>
	<DOCNO>NCT02276040</DOCNO>
	<brief_summary>The purpose study quantify total blood serum level bupivacaine OrthoPAT® collect blood 2 hour 5 hour postoperatively . Hypothesis : Filtered blood OrthoPAT® autotransfusion system contain low undetectable level bupivacaine HCL . Reinfusion collect blood OrthoPAT® device use conjunction periarticular bupivicaine injection pose bupivocaine toxicity risk patient undergoing total joint arthroplasty .</brief_summary>
	<brief_title>Serum Levels Bupivacaine Autotransfusion Drains Following Total Joint Arthroplasty</brief_title>
	<detailed_description>Total joint arthroplasty ( TJA ) commonly perform surgical procedure result considerable postoperative pain limit social functional recovery return quality life . Traditionally , pain control follow TJA conduct parenteral oral narcotic . Recently , number study demonstrate efficacy multimodal analgesia follow variety surgical procedures.1-2 These multimodal regimen vary consist number medication include narcotic , non-steroidal anti-inflammatory , anti-epileptics , peripheral nerve block among others . These multimodal regimen associate reduction use opioid analgesic , lead few opioid-associated adverse events.3-5 One newest modality introduce market liposomal bupivacaine , trade name Exparel . The advertised advantage liposomal bupivacaine compare bupivacaine HCl long duration analgesia owe gradual release liposome . Liposomal bupivacaine employ periarticular injection conclusion TJAs aid post-operative pain control . Patients receive periarticular injection liposomal bupivacaine intra-operatively TJA . At conclusion procedure , specialize intra-articular drain ( OrthoPAT® ) place . The OrthoPAT® perioperative autotransfusion system collect patient 's blood immediate postoperative period allows transfuse patient floor . A potential risk , although low , concern bupivicaine toxicity . Toxicity bupivicaine associate central nervous system issue ( seizure ) cardiac toxicity . Toxicity dose dependent recommend level exceed 400mg/24 hr period . With autotransfusion , theoretical concern blood , potentially increased level bupivicaine , could reinfused vascular system create toxicity .</detailed_description>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>Patients undergo primary total joint arthroplasty use periarticular bupivicaine liposomal bupivicaine OrthoPAT® auto reinfusion system . At least 18 year age . Allergy bupivacaine . Allergy epinephrine . Patients present primary TJA Patients TJA without OrthoPAT® auto reinfusion system . Patients age 18 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Arthroplasty</keyword>
	<keyword>Knee Replacement</keyword>
	<keyword>Analgesia</keyword>
	<keyword>pain</keyword>
</DOC>